Trial Profile

Phase 1 trial of YTX-9184 for the treatment of dementia with Lewy Bodies

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 13 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs YTX-9184 (Primary)
Indications Dementia; Lewy body disease
Focus Adverse reactions
Sponsors Kineta; TuHURA Biosciences; Yumanity Therapeutics

Most Recent Events

30 Jun 2025 According to TuHURA Biosciences media release, Kineta has been acquired and merged into TuHURA Biosciences.
19 Dec 2022 According to a Kineta media release, Yumanity Therapeutics was merged with Kineta to form Kineta.
12 Aug 2021 According to a Yumanity Therapeutics media release, this study is expected to begin later this year.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com